Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697679 | 0.77 | SMN1; SMN2 (0.42) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL17584432 | 0.77 | CYP11B1 (0.38) | APP | |
| SCHEMBL2433326 | 0.77 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL12523295 | 0.76 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL18263424 | 0.76 | AKT1 (0.39) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL2221457 | 0.76 | PLAU (0.38) | NPC1RAB9ASMN1; SMN2HSD17B10CHRNB2 | |
| SCHEMBL15578234 | 0.74 | SMN1; SMN2 (0.36) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL25242333 | 0.74 | CHRNB2 (0.33) | CHRNB2CHRNA4 | |
| SCHEMBL31067893 | 0.72 | — | — | |
| SCHEMBL25217332 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| WO-2017182418-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017182418-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | APP 34/4885NPC1 54/4885RAB9A 3891/4885 |
| US-10781205-B2 | Conjugates comprising RIPK2 inhibitors | RIPK2, RIPK1, RIPK4 | APP 1570/4885NPC1 2553/4885RAB9A 1808/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | APP 34/4885NPC1 55/4885RAB9A 3962/4885 |
| US-20190119271-A1 | CONJUGATES COMPRISING RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | APP 1570/4885NPC1 2553/4885RAB9A 1808/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | APP 34/4885NPC1 54/4885RAB9A 3891/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | APP 34/4885NPC1 55/4885RAB9A 3962/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | APP 34/4885NPC1 55/4885RAB9A 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.